Low but Real Risk for Malignancy in Branch Duct Intraductal Papillary Mucinous Neoplasms

Although ongoing surveillance should be considered, five-year risk for pancreatic cancer was only 6%.

The risk for malignant transformation of branch duct intraductal papillary mucinous neoplasms (BD-IPMNs) is unclear.

In the current retrospective study, researchers assessed the risk for development of malignancy (high-grade dysplasia or invasive neoplasm) in 577 patients with suspected or presumed BD-IPMNs. Most patients (83%) were asymptomatic at the time of diagnosis, and 63% underwent a minimum of one endoscopic ultrasound. The median follow-up time was 82 months; 63% were followed for >5 years, and 21% for >10 years.

Incidence of malignancy after at least 5 years of follow-up was 6%, and incidence of invasive cancer was 4%. The overall age-standardized incidence ratio for malignancy in patients with BD-IPMNs without worrisome features of…

Reviewing Author

Douglas G. Adler, MD, FACG, AGAF, FASGE

Disclosures

Consultant/Advisory BoardBSC; Merit; Olympus

Speaker’s BureauAbbVie

Editorial BoardsGastrointestinal Endoscopy

Douglas G. Adler, MD, FACG, AGAF, FASGE

Disclosures

Consultant/Advisory BoardBSC; Merit; Olympus

Speaker’s BureauAbbVie

Editorial BoardsGastrointestinal Endoscopy

Low but Real Risk for Malignancy in Branch Duct Intraductal Papillary Mucinous Neoplasms

Topics

Reviewing Author